BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment

Winter, Georg E., Mayer, Andreas, Buckley, Dennis L., Erb, Michael A., Roderick, Justine E., Vittori, Sarah, Reyes, Jaime M., di Iulio, Julia +15 more·2017·Molecular Cell

DOI 10.1016/j.molcel.2017.06.004

Cited by (469)

Items 301–400 of 469

Hypoxia-sensitive macrocycle inclusion complexes for targeted protein degradation
Jiachan Lin, Wenyan Wang, An‐Kang Ying, Zirui Chen, Dan Zhang, Chendi Ding, Xiaowei Zeng, Dong‐Sheng Guo, Hongzhong Chen · 2025 · Journal of Controlled Release
Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy
Michael Y. He, Michael M. Halford, Ruofei Liu, James P. Roy, Zoe L. Grant, Leigh Coultas, Niko Thio, Omer Gilan, Yih-Chih Chan, Mark A. Dawson et al. · 2021 · Communications Biology
BRD4 is involved in viral exacerbation of chronic obstructive pulmonary disease
Yifei Duan, Siyi Zhou, Jianmiao Wang · 2023 · Respiratory Research
SETD6 Regulates E2-Dependent Human Papillomavirus Transcription
Leny Jose, Elliot J. Androphy, Marsha L. DeSmet · 2022 · Journal of Virology
A synthetic KLHL20 ligand to validate CUL3 KLHL20 as a potent E3 ligase for targeted protein degradation
Brian M. Farrell, Fabian Gerth, Cheng-Hao R. Yang, Johannes T.‐H. Yeh · 2022 · Genes & Development
Constitutive protein degradation induces acute cell death via proteolysis products
Sihan Chen, Sumit Prakash, Elizabeth Helgason, Caroline L. Gilchrist, Lillian R. Kenner, Rajini Srinivasan, Tim Sterne‐Weiler, Marc A. Hafner, Robert Piskol, Erin C. Dueber et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Klaudia Giercuszkiewicz-Haśnik, BEATA IZABELA MORAK-MŁODAWSKA, Małgorzata Jeleń · 2026 · Molecules
A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4
Ziwei Song, Jin Li, Yijie He, Xiaokun Wang, Jianan Tian, Yun Wu · 2024 · International Immunopharmacology
Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity
Sicong Zhang, Robert G. Roeder · 2024 · Nature Structural & Molecular Biology
Catalytic-independent functions of the Integrator–PP2A complex (INTAC) confer sensitivity to BET inhibition
Pengyu Fan, Xue-Ying Shang, Aixia Song, Shuo Chen, Run-Yuan Mao, Jingchuan Ma, Jiwei Chen, Zhenning Wang, Hai Zheng, Bolin Tao et al. · 2025 · Nature Chemical Biology
Transcription Pause and Escape in Neurodevelopmental Disorders
Kristel N. Eigenhuis, Hedda B. Somsen, Debbie L. C. van den Berg · 2022 · Frontiers in Neuroscience
Discovery of a Potent and Selective Degrader for USP7
Yuan Pei, Jingfeng Fu, Yunkai Shi, Mengmeng Zhang, Guanghao Luo, Xiaomin Luo, Ning Song, Tian Mi, Yaxi Yang, Jia Xuan Li et al. · 2022 · Angewandte Chemie
BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells
Anne‐Marie W. Turner, Frances M. Bashore, Shane D. Falcinelli, Joshua A. Fox, Alana L. Keller, Anthony D. Fenton, Renee F. Geyer, Brigitte Allard, Jennifer Kirchherr, Nancie M. Archin et al. · 2025 · Journal of Virology
Targeting transcriptional machinery to inhibit enhancer-driven gene expression in heart failure
Rachel A Minerath, Duane D. Hall, Chad Eric Grueter · 2019 · Heart Failure Reviews
Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification
Lauren S. Y. Wood, Min Huang, Jasmine C. Zeki, Miao Gong, Jordan S. Taylor, Hiroyuki Shimada, Bill Chiu · 2021 · Journal of Pediatric Surgery
Genomic Occupancy of the Bromodomain Protein Bdf3 Is Dynamic during Differentiation of African Trypanosomes from Bloodstream to Procyclic Forms
Ethan C. Ashby, Lucinda Paddock, Hannah L. Betts, Jingwen Liao, Geneva Miller, Anya Porter, Lindsey M. Rollosson, Carrie Saada, ERIC K. Y. TANG, Serenity J. Wade et al. · 2022 · mSphere
Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia
Miaomiao Xu, Jingfeng Fu, Yuan Pei, Mengna Li, Weijuan Kan, Ruyu Yan, Chaoyue Xia, Jingkun Ma, Peipei Wang, Yan Zhang et al. · 2024 · Journal of Medicinal Chemistry
A transcription coupling model for how enhancers communicate with their target genes
Elisabeth Altendorfer, Stefan Mundlos, Andreas Mayer · 2025 · Nature Structural & Molecular Biology
Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies
Francesco Bertoni, Anastasios Stathis · 2019 · Current Opinion in Hematology
Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
Xinrui Yang, Yin He, Richard D. Kim, Jason B. Fleming, Hao Xie · 2020 · Targeted Oncology
Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design
Robert D. Kuchta, Christopher Heim, Alexander Herrmann, Samuel A. Maiwald, Yuen Lam Dora Ng, Izidor Sosič, Tim Keuler, Jan Krönke, Michael Gütschow, Marcus D. Hartmann et al. · 2023 · RSC Chemical Biology
In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor
Giulia Apprato, Giulia D’Agostini, Paolo Rossetti, Giuseppe Ermondi, Giulia Caron · 2023 · Molecules
Progress on Small-Molecule Proteolysis-Targeting Chimeras
Wenhai Huang, Beibei Wang, Zhimin Zhang, Chixiao Zhang, Shenxin Zeng, Zhengrong Shen · 2019 · Future Medicinal Chemistry
Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
Simon J. Hogg, Olga Motorna, Conor J. Kearney, Emily B. Derrick, Imran G. House, Izabela Todorovski, Madison J. Kelly, Magnus Zethoven, Kenneth D. Bromberg, Albert Lai et al. · 2022 · Clinical Epigenetics
Comparative analysis of biophysical methods for monitoring protein proximity induction in the development of small molecule degraders
Kamil Przytulski, Przemysław Glaza, Katarzyna Brach, Maria Sagan, Grzegorz Statkiewicz, Jan Klajn, Michał Walczak · 2023 · Biochimica et Biophysica Acta (BBA) - General Subjects
Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains
Chuhui Huang, Claire L. Harris, Ghizal Siddiqui, Manuela Jörg · 2025 · ACS Pharmacology & Translational Science
Bromodomain-containing 4 as a therapeutic target in inflammatory bowel diseases and colorectal cancer
Irene Marafini, Rachele Frascatani, Marco Colella, Elena De Cristofaro, Giovanni Monteleone · 2025 · Frontiers in Pharmacology
The BRD4-nucleosome interaction is enhanced modestly and non-selectively by histone acetylation
L. Lambrechts, Xavier J. Reid, Lucas Kambanis, Clement Luong, Erekle Kobakhidze, Andrea Daners, Yichen Zhong, Karishma Patel, Charlotte Franck, Hakimeh Moghaddas Sani et al. · 2025 · Nucleic Acids Research
Proteasome Cap Targeting Chimeras for Ubiquitination‐Independent Targeted Protein Degradation
Chen Song, Qi Liu, Tingjian Wang, Yan Y. Song, Logan H. Sigua, Paul M.C. Park, Scott B. Ficarro, Sunwoo Liv Lee, S. Picaud, P. Filippakopoulos et al. · 2026 · Angewandte Chemie International Edition
Data-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability
Yuki Murakami, Shoichi Ishida, Nobuo Cho, Hitomi Yuki, Masateru Ohta, Teruki Honma, Yosuke Demizu, Kei Terayama · 2026 · JACS Au
BET degrader exhibits lower antiproliferative activity than its inhibitor via EGR1 recruiting septins to promote E2F1-3 transcription in triple-negative breast cancer
Nan Liu, Shuai Wang, Munan Li, Nan Zhao, Deyu Wang, Rui Zhang, Mingxin Yu, Luoyi Zhao, Siwei Zhang, Fangbin Han et al. · 2024 · Pharmacological Research
What Is the BET on Solid Tumors?
P. Filippakopoulos · 2018 · Journal of Clinical Oncology
Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy
Nobumichi Ohoka · 2018 · YAKUGAKU ZASSHI
Cyclin-Dependent Kinase 9 Inhibition Suppresses Necroptosis and Pyroptosis in the Progress of Endotoxemia
Jiao Li, Huimin Mao, Yue Pan, Houxuan Li, Lang Lei · 2020 · Inflammation
Use of Aldehyde–Alkyne–Amine Couplings to Generate Medicinal Chemistry-Relevant Linkers
Andrew McGown, Vesna Vetma, Damien Crépin, Yan Lin, Claire Adcock, Conner Craigon, Jordan Nafie, Daniel von Emloh, Léa Sutton, Kiera Bailey et al. · 2025 · ACS Medicinal Chemistry Letters
KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity
Yulong Qiang, Jiachen Fan, Chuanshuai Xie, Leilei Yan, Xiaofei Song, Nan Zhang, Yan Lin, Jie Xiong, Wei Zhang, Yu Liu et al. · 2024 · Cancer Research
Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Maohua Cai, Jinyun Dong, Haobin Li, Jiang‐Jiang Qin · 2022 · Current Medicinal Chemistry
Enabling cancer target validation with genetically encoded systems for ligand-induced protein degradation
Yuxiang Zhang, Michael A. Erb · 2021 · Current Research in Chemical Biology
Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma
Jian Wu, Emily Chu, Barry A. Paul, Yubin Kang · 2022 · Cancers
CTDP1 and RPB7 stabilize Pol II and permit reinitiation
Haonan Zheng, Qiqin Xu, Dexun Ji, Boqin Yang, Xiong Ji · 2025 · Nature Communications
Harnessing targeted protein degradation to potentiate cancer immunotherapy: from molecular mechanisms to delivery strategies
Ye Liu, Ihsan Ullah, Youyong Yuan, Jun Wang · 2026 · Advanced Drug Delivery Reviews
Proximity Binding Assay for PROTAC Ternary Complex Analysis
Irene Ponzo, Alice Soldà, Charlotte Crowe, Göran Dahl, Tereza Jahodová, Andreas Heerwig, Stefan Geschwindner, Alessio Ciulli, Ulrich Rant · 2026 · ACS Sensors
Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
Charlotte Crowe, Alessio Ciulli · 2026 · Chemical Reviews
Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?
Dominic D. G. Owens, Matthew E. R. Maitland, C.H. Arrowsmith, Dalia Baršytė-Lovejoy · 2024 · Annual Review of Cancer Biology
Ectopic expression of testis-specific transcription elongation factor in driving cancer
Bin Zheng, Marta Iwanaszko, Shimaa Hassan AbdelAziz Soliman, Yukitomo Ishi, Sarah R. Gold, Ruxuan Qiu, Benjamin C. Howard, Madhurima Das, Zibo Zhao, Rintaro Hashizume et al. · 2025 · Science Advances
Stick it to E3s
Matthias Brand, Georg E. Winter · 2019 · Nature Chemical Biology
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
Chiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, Carmelo Moscatello, Eugenio Gaudio, Luciano Cascione, Sara Napoli, Cesare Rech, Andrea Testa, Chiara Maniaci et al. · 2021 · Exploration of Targeted Anti-tumor Therapy
Design, synthesis, biological evaluation, and molecular docking of 1,7-dibenzyl-substituted theophylline derivatives as novel BRD4-BD1-selective inhibitors
Yingjie Chang, Jinge Zhang, Shuangshuang Yang, Wanying Lu, Lina Ding, Yi‐Chao Zheng, Wen Li · 2021 · Medicinal Chemistry Research
Exploiting a rodent cell block for intrinsic resistance to HIV-1 gene expression in human T cells
Ryan T. Behrens, Jyothi Krishnaswamy Rajashekar, James W. Bruce, Edward L. Evans, Amelia M. Hansen, Natalia A. Salazar-Quiroz, Lacy M. Simons, Paul Ahlquist, Judd F. Hultquist, Priti Kumar et al. · 2023 · mBio
Inducible Protein Degradation to Understand Genome Architecture
Alexi M Tallan, Benjamin Z. Stanton · 2021 · Biochemistry
Targeting Cancer at the Intersection of Signaling and Epigenetics
Stephanie L. Guerra, Karen M. Cichowski · 2018 · Annual Review of Cancer Biology
Rapid-kinetics degron benchmarking reveals off-target activities and mixed agonism-antagonism of MYB inhibitors
Taku Harada, Monika W. Perez, Jérémie Kalfon, Flora Dievenich Braes, Rashad Batley, Kenneth Eagle, Behnam Nabet, Becky S. Leifer, Jasmin A. Kruell, Vikram R. Paralkar et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
Topical BET PROTACs for locally restricted protein degradation in the lung
Martin Hemmerling, Jianming Liu, Antonio Piras, Rikard Pehrson, Ulf Hedström, Carlo Cassani, Beatrice Ranieri, Karolina Kwapień, Karin Ribbing, Cecilia Forss et al. · 2025 · RSC Medicinal Chemistry
Multiple functions of BRD4 in maintaining genomic stability in cancers
Zifeng Huang, Tong Chu, Wenzhe Ma · 2025 · Biochemical and Biophysical Research Communications
Advances in light-controllable PROTACs: Design strategies, therapeutic applications and current challenges
Ji Wu, Ziyue Wang, Shi-Xuan Tan, Tingyu Li, Bingbing Chen, Qiqi Chen, Hao Li, Jin-Bo Niu, Xiang-Jing Fu, Jian Song et al. · 2025 · Bioorganic Chemistry
Efficient Synthesis and Docking Analysis of Selective CDK9 Inhibitor NVP-2
Abdusaid Saidahmatov, Xuewu Liang, Yuqiang Shi, Xu Han, Hong Shu Liu · 2021 · Pharmaceutical Fronts
Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity
Praveen Kumar Tiwari, Sai Reddy Doda, Raghu Vannam, Manish S. Hudlikar, Drew A. Harrison, Samuel Ojeda, Sumit Rai, Ann-Sophie Koglin, Angelique Gilbert, Christopher J. Ott · 2024 · Bioorganic & Medicinal Chemistry Letters
Next generation epigenetic modulators to target myeloid neoplasms
Daniel Sasca, Borhane Guezguez, Michael W.M. Kühn · 2021 · Current Opinion in Hematology
Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs
Yuting Cao, Alexandra L. Harris, Alessio Ciulli · 2025 · Nature Protocols
Design, synthesis, and biological evaluation of novel PROTACs based on unnatural dipeptide CRBN ligands
Kun Huang, Peng Luo, Caihua Li, Nan Huang, Kun Yao, Xiong-Xiong Lan, Ling-Feng Du, Yan Miao, Qing Hua Tang, Ying Xu et al. · 2025 · European Journal of Medicinal Chemistry
Targeted degradation of BRD4 by PROTACs: advances in cancer therapy
Yanyun Hong, Xiang Liu, Yanfang Li, Mengting Yu, Caolin Wang, Cunpeng Nie, Shan Xu · 2026 · Chemical Communications
The Promoter-Proximal Pause: A Decision Point Governing RNA Polymerase II Fate
Usman Hyder, David L. Bentley · 2026 · Annual Review of Biochemistry
Histone acetylation-dependent clustering of BRD2 instructs transcription dynamics
Niyazi Umut Erdogdu, Sukanya Guhathakurta, Ronald Oellers, Maria Shvedunova, José A. Morín, Eric M. Patrick, Janine Seyfferth, Ward Deboutte, Alejandro Gómez-Aulí, Gerhard Mittler et al. · 2026 · Nature Genetics
Medicinal chemistry approaches to the discovery and development of p300/CBP inhibitors for cancer therapy
Huan Wang, Dandan Song, Miao Miao, Simeng Wu, Jiao Wang, Zhe Huang, Hao Ding · 2025 · European Journal of Medicinal Chemistry
Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID
Suman Shrestha, Matthew E. R. Maitland, Jing Li, Shili Duan, David Y. Nie, Jonathan R. St‐Germain, Michael Kanaris, Dalia Baršytė-Lovejoy, C.H. Arrowsmith, Brian Raught · 2025 · Nature Communications
Cell‐type‐specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma
Alexandra J Rose, Mercedes M Fleming, Jeffrey C. Francis, Jian Ning, Anton Patrikeev, Ritika Chauhan, Kevin Joseph Harrington, Amanda Swain · 2023 · The Journal of Pathology
Dynamic O-GlcNAcylation and phosphorylation attract and expel proteins from RNA polymerase II to regulate mRNA maturation
Aishwarya Gondane, Harri M. Itkonen · 2025 · Journal of Biomedical Science
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Kristin M. Riching, Sarah D. Mahan, Marjeta Urh, Danette L. Daniels · 2020 · Journal of Visualized Experiments
Enhancers in T Cell development and malignant lesions
Tong Zhang, Lin Zou · 2024 · Cell Death Discovery
Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics
Mingyao Huang, Fang Wei, Jilong Cao, Hongzhou Jiang · 2025 · Bioorganic Chemistry
A triple-action PROTAC for wild-type p53 cancer therapy
Gregory H. Bird, Utsarga Adhikary, Michael J. Schmidt, Marina Godes, Bethany M. Tesar, Christina M. Camara, João A. Paulo, Julia F. Vidlak, Thomas M. DeAngelo, Marilyn Marquez et al. · 2025 · Cell Reports Medicine
The role of histone modifications in transcription regulation upon DNA damage
Angelina Job Kolady, Siyao Wang · 2025 · FEBS Letters
BRD2 bridges TFIID and MOF-H4K16ac-containing nucleosomes to promote transcriptional initiation
Bin Zheng, Ruxuan Qiu, Sarah R. Gold, Marta Iwanaszko, Yuki Aoi, Benjamin Charles Howard, Madhurima Das, Ali Shilatifard · 2025 · Molecular Cell
Superenhancers shape the landscape and repair dynamics of transcription-associated DNA breaks in cancer
Osama Hidmi, Diala Shatleh, Sara Oster Flayshman, Jonathan Monin, Rami I. Aqeilan · 2026 · Science Advances
Discovery of SKP2‐Recruiting PROTACs for Target Protein Degradation
Guanjun Dong, Aima Huang, Ziqing Zhao, Bikai Lai, Xin Pan, Huiyu Yang, Xiaohan Xu, Tianwei Wang, Fangchen Zhao, Zhimin Zhang et al. · 2026 · Advanced Science
BRD2 upregulation as a pan-cancer adaptive resistance mechanism to BET inhibition
Suyakarn Archasappawat, Juliette Jacques, Eunjung Lee, Chang‐Il Hwang · 2026 · Cellular & Molecular Biology Letters
Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases
Yikang Ji, Wantao Chen, Xu Wang · 2024 · Journal of Pharmacology and Experimental Therapeutics
Chemische Epigenetik: der Einfluss chemischer und chemo‐biologischer Techniken auf die Zielstruktur‐Validierung von Bromodomänen
Matthias Schiedel, Mustafa Moroglu, David M. H. Ascough, Anna E. R. Chamberlain, Jos J. A. G. Kamps, Angelina R. Sekirnik, Stuart J. Conway · 2019 · Angewandte Chemie
The Elongation Regulators and Architectural Proteins as New Participants of Eukaryotic Gene Transcription
Nadezhda E. Vorobyeva, Marina Yu. Mazina · 2021 · Russian Journal of Genetics
Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and Avidity
Satomi Imaide, Kristin M. Riching, Vesna Vetma, Claire Whitworth, Scott J. Hughes, Nicole B. Trainor, Sarah D. Mahan, Nancy Murphy, Kwok-Ho Chan, Andrea Testa et al. · 2020 · ChemRxiv
Proximity Biosensor Assay for PROTAC Ternary Complex Analysis
Irene Ponzo, Alice Soldà, Charlotte Crowe, Göran Dahl, Stefan Geschwindner, Alessio Ciulli, Ulrich Rant · 2024 · ChemRxiv
Cis and Trans Regulatory Mechanisms of ecDNA Segregation
Yi-Peng Xie, J. Lim, Wenyue Liu, C. Gilbreath, Xiaohui Sun, Kailiang Qiao, Y. Kim, Si-Han Wu · 2026 · bioRxiv
Rewiring DNA repair with PARP-based chemical inducers of proximity
Bryce da Camara, Eric M. Bilotta, Erin Broderick, Ashwini Premashankar, Paige A. Barta, Trever R. Carter, Lauren M. Hargis, Daniel Durocher, Michael A. Erb · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Binding of NF-Y to transposable elements in mouse and human cells
Mirko Ronzio, Andrea Bernardini, Alberto Gallo, Roberto Mantovani, Diletta Dolfini · 2025 · Mobile DNA
Chromatin Regulatory Targets for Anticancer Therapeutics
Paige A. Barta, Trever R. Carter, Michael A. Erb · 2025 · Chemical Reviews
A Modular Platform for Quantitative Two-Color Bioluminescence Combining NanoLuc and Red-Shifted NanoPrism Luciferases
Karilyn Porter, Mike Killoran, Robin Hurst, Mark Klein, Debayan De Bakshi, Rahele Esmatpour, Lance P. Encell, Felipe Gama-Franceschi, Joseph Bessetti, Kristin M. Riching et al. · 2026 · ACS Chemical Biology
Cis and trans regulatory mechanisms of extrachromosomal DNA segregation
Yi-Peng Xie, J. Lim, Wenyue Liu, C. Gilbreath, Xiaohui Sun, Kailiang Qiao, Y. Kim, Si-Han Wu · 2026 · Nature Cell Biology
Advances in selective inhibitors targeting the BD1 and BD2 domains of BET proteins
Jia‐Yao Xie, Ye-Wei Pang, Cheng-Lin Yu, Yuyan Li, Lei Shi · 2026 · European Journal of Medicinal Chemistry
DCAF11-dependent molecular glue degrader activated by glutathionylation
Hojong Yoon, Franziska Wachter, Katharine Barrett, Cyrus Jin, Anna Rodríguez-Pöhnlein, Justine C. Rutter, Ryan J. Lumpkin, Rebecca J. Metivier, Katherine A. Donovan, Kheewoong Baek et al. · 2026 · Nature
An end-to-end workflow to study newly synthesized mRNA following rapid protein depletion in Saccharomyces cerevisiae
John B. Ridenour, Rafał Donczew · 2024 · BMC Methods
RNA kinetics influence the response to transcriptional perturbation in leukaemia cell lines
Izabela Todorovski, Mary‐Jane Tsang, Breon Feran, Zheng Fan, Sreeja Gadipally, David Yoannidis, Isabella Y. Kong, Stefan Bjelosevic, S. Rivera, Olivia Voulgaris et al. · 2024 · NAR Cancer
The ESCRT protein CHMP5 promotes T cell leukemia by enabling BRD4-p300-dependent transcription
Katharine Umphred-Wilson, Shashikala Ratnayake, Qianzi Tang, Rui Wang, Sneha Ghosh Chaudhary, Ballachanda N. Devaiah, Josephine Trichka, Jan Wiśniewski, Lan Zhou, Qingrong Chen et al. · 2025 · Nature Communications
BRD4 binds the nucleosome via both histone and DNA interactions
Jiang Zhu, Erik M. Leith, Erin N. O’Donnell, B.P. Manzano, Shwu-Yuan Wu, Cheng‐Ming Chiang, Jean‐Paul Armache, Song Tan · 2026 · Molecular Cell
Mathematical Framework for Hierarchical Cell Identity Control by Collective Enhancer Dynamics
Anton Grishechkin, Abhirup Mukherjee, Omer Karin · 2025 · PRX Life
Immediate and Selective Control of Protein Abundance Using the dTAG System
Behnam Nabet, Nathanael S. Gray · 2020 · Royal Society of Chemistry eBooks
Epigenetic Targeting of Cancer
Jacob R. Cawley · 2023 · CABI eBooks
Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog Pathway Inhibitor-1
Meropi Bagka, Hyeonyi Choi, Margaux Héritier, Léonardo Scapozza, Yibo Wu, Sascha Hoogendoorn · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
Activity-based profiling of cullin-RING ligase networks by conformation-specific probes
Lukas T. Henneberg, Jaspal Singh, David M. Duda, Kheewoong Baek, David Yanishevski, Peter J. Murray, Matthias Mann, Sachdev S. Sidhu, Brenda Arlene Schulman · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
Catalytic-independent functions of INTAC in conferring sensitivity to BET inhibition
Pengyu Fan, Xue-Ying Shang, Aixia Song, Shuo Chen, Run-Yuan Mao, Jiwei Chen, Zhenning Wang, Hai Zheng, Bolin Tao, Wei Xu et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
TGF-β1 induces super-enhancers at the loci of the EMT-related genes in human keratinocyte HaCaT cells
Kana Takeda, Yoshiyuki Nagaoka, Sachio Tamaoki, Mitsutoki Hatta · 2025 · Gene